Wall Street brokerages forecast that Achieve Life Sciences Inc (NASDAQ:ACHV) will announce earnings of ($0.22) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Achieve Life Sciences’ earnings. Achieve Life Sciences posted earnings per share of ($0.71) in the same quarter last year, which indicates a positive year-over-year growth rate of 69%. The business is expected to issue its next earnings results on Wednesday, November 6th.
According to Zacks, analysts expect that Achieve Life Sciences will report full year earnings of ($1.60) per share for the current year, with EPS estimates ranging from ($1.83) to ($1.36). For the next financial year, analysts expect that the company will report earnings of ($1.49) per share, with EPS estimates ranging from ($1.82) to ($1.16). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Achieve Life Sciences.
Achieve Life Sciences (NASDAQ:ACHV) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.17).
Several hedge funds and other institutional investors have recently made changes to their positions in ACHV. Jane Street Group LLC purchased a new position in shares of Achieve Life Sciences during the 2nd quarter valued at about $32,000. Searle & CO. raised its holdings in shares of Achieve Life Sciences by 80.4% during the 2nd quarter. Searle & CO. now owns 132,592 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 59,092 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Achieve Life Sciences by 152.2% during the 2nd quarter. Vanguard Group Inc. now owns 274,519 shares of the biopharmaceutical company’s stock valued at $530,000 after buying an additional 165,667 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Achieve Life Sciences by 12.5% during the 2nd quarter. Renaissance Technologies LLC now owns 321,268 shares of the biopharmaceutical company’s stock valued at $620,000 after buying an additional 35,607 shares in the last quarter. Finally, Sio Capital Management LLC raised its holdings in shares of Achieve Life Sciences by 24.4% during the 2nd quarter. Sio Capital Management LLC now owns 524,413 shares of the biopharmaceutical company’s stock valued at $1,012,000 after buying an additional 102,934 shares in the last quarter. 18.63% of the stock is currently owned by institutional investors.
Shares of NASDAQ:ACHV traded up $0.03 on Thursday, hitting $1.58. The company’s stock had a trading volume of 59,495 shares, compared to its average volume of 118,429. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.62 and a current ratio of 3.62. Achieve Life Sciences has a 1 year low of $1.04 and a 1 year high of $4.63. The company has a 50-day simple moving average of $1.99 and a 200 day simple moving average of $2.69.
Achieve Life Sciences Company Profile
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms.
Read More: Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.